Financial Data and Key Metrics Changes - Net sales for Q3 2025 were $15.9 million, reflecting a 44% decrease from $28.3 million in Q3 2024, primarily due to the transition of the largest customer to another supplier [14] - Gross profit for Q3 2025 was $2.3 million, a 64% decrease from $6.2 million in Q3 2024, with a gross margin of 14%, down from 22% in Q3 2024 [14][15] - Adjusted EBITDA for Q3 2025 was $50,000, an improvement from negative $200,000 in Q2 2025 and negative $400,000 in Q1 2025 [16] - Cash and cash equivalents increased to $23.7 million from $18.4 million at the end of Q2 2025, driven by the issuance of common stock [16][17] Business Line Data and Key Metrics Changes - The company signed several new long-term product purchasing agreements, including a notable three-year commitment with a dialysis center in Southern Florida, potentially generating approximately $1 million in annualized net sales [8] - Expanded product purchase agreement with the largest provider of dialysis in skilled nursing facilities in the U.S., effective for three years [9] Market Data and Key Metrics Changes - The largest customer represented 12% of net sales in Q3 2025, indicating reduced dependence on any single customer due to successful diversification efforts [10] - The company is actively pursuing business development opportunities across various customer segments and geographic markets, reinforcing optimism about growth in 2026 and beyond [8] Company Strategy and Development Direction - The company is focused on right-sizing its organization to enhance operational efficiency while maintaining high-quality customer service [4][5] - Strategic decisions made earlier in the year are translating into tangible results, with over 80% of customers operating under long-term agreements, providing stability and revenue visibility [4][6] - The introduction of a new bicarbonate cartridge is expected to significantly grow the higher-margin product opportunity [25] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance targets and sustainable profitability moving forward [6][7] - The transition period with the largest customer is expected to resolve within the current quarter, with ongoing discussions regarding future commitments [21][24] - The company anticipates providing forward revenue guidance for 2026 early in the year, with plans for potential acquisitions to enhance growth [22][24] Other Important Information - The company is actively restructuring its operations to align with changes in the customer base, focusing on improving efficiency and reducing costs [12][30] - A facility closure was executed to consolidate manufacturing activities, which is expected to reduce operating expenses [32] Q&A Session Summary Question: When will the situation with the former largest customer be resolved? - Management expects resolution within the current quarter and is in contract discussions [21] Question: When will forward revenue guidance for 2026 be provided? - Guidance is typically provided early in the year, with visibility expected during the fourth quarter earnings release [24] Question: What are the key prospects for the bicarbonate disposables business? - The introduction of the bicarbonate cartridge is expected to significantly grow this higher-margin product opportunity [25] Question: How is the company balancing organizational restructuring with investments? - The company is reallocating resources to focus on growth opportunities while winding down unsupported operations [28] Question: Where is there room for improving gross margin? - Immediate focus is on labor costs, with long-term potential in reducing materials and distribution costs [30][31] Question: Update on West Coast expansion and home dialysis business? - The West Coast is seen as a growth area, with potential announcements on new customers expected soon; home dialysis remains a small but growing segment [38][40][41]

Financial Data and Key Metrics Changes - Net sales for Q3 2025 were $15.9 million, reflecting a 44% decrease from $28.3 million in Q3 2024, primarily due to the transition of the largest customer to another supplier [14] - Gross profit for Q3 2025 was $2.3 million, a 64% decrease from $6.2 million in Q3 2024 [14] - Adjusted EBITDA for Q3 2025 was $50,000, an improvement from negative $200,000 in Q2 2025 and negative $400,000 in Q1 2025 [16] - Cash and cash equivalents increased to $23.7 million from $18.4 million at the end of Q2 2025 [17] Business Line Data and Key Metrics Changes - The company reported a gross margin of 14% for Q3 2025, down from 22% in Q3 2024, but excluding restructuring costs, gross margin was 18%, showing improvement over the first two quarters of 2025 [15] - The transition of the largest customer represented 12% of net sales in Q3 2025, indicating reduced dependence on any single customer [10] Market Data and Key Metrics Changes - The company signed several new long-term product purchasing agreements during Q3 2025, including a notable three-year commitment with a dialysis center in Southern Florida, potentially generating approximately $1 million in annualized net sales [8] - Discussions with the formerly largest customer are ongoing, with expectations to continue supplying them through the end of the year [9] Company Strategy and Development Direction - The company is focused on optimizing its organizational structure to align with current scale while enhancing operational efficiency and customer service [5] - Strategic decisions made earlier in the year are translating into tangible results, with over 80% of customers operating under long-term agreements, providing stability and revenue visibility [4] - The company is actively pursuing business development opportunities, including potential acquisitions, leveraging its strong cash position [24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving full-year guidance targets and sustainable profitability moving forward [6] - The company anticipates providing forward revenue guidance for 2026 early in the year, with expectations to announce business development impacts shortly [24] Other Important Information - The company is expanding its customer base on the West Coast and is considering establishing a facility there due to growing customer demand [38] - The at-home dialysis market is seen as a significant growth opportunity, with expectations for continued growth in this segment [40] Q&A Session Summary Question: Resolution timeline with former largest customer - Management expects the situation to resolve within the current quarter and is in contract discussions [21] Question: Forward revenue guidance for 2026 - Guidance is typically provided early in the year, with visibility expected during the fourth quarter earnings release [24] Question: Key prospects for bicarbonate disposables business - The introduction of the bicarbonate cartridge is expected to significantly grow this higher margin product opportunity [25] Question: Balancing organizational restructuring with investments - The company is managing resource allocation carefully to focus on growth opportunities while winding down unsupported operations [28] Question: Areas for improving gross margin - Immediate focus is on labor costs, with long-term potential in materials and distribution efficiencies [30] Question: Background on facility closure - A facility was closed as part of consolidation efforts, with expenses being offloaded [32] Question: Update on West Coast expansion and home dialysis business - The West Coast is a focus area for customer acquisition, and the at-home market is expected to grow significantly [38][40]

Core Points - Embecta Corp. is transitioning from a company focused solely on insulin delivery to a broader medical supplies company, leveraging its 100-year legacy in the industry [1][3] - The company will host a conference call on November 25, 2025, at 8:00 a.m. ET to discuss its fiscal fourth quarter and full year 2025 financial results, along with preliminary financial guidance for fiscal year 2026 [1][2] Company Overview - Embecta employs approximately 2,000 employees globally and aims to improve lives through innovative solutions and partnerships [3] - The company is committed to advancing its legacy in insulin delivery while expanding its product offerings in the medical supplies sector [3]

Core View - United-Guardian, Inc. has experienced a significant decline in both sales and net income for the third quarter of 2025, with net sales falling 26% year-over-year to $2.26 million and net income dropping to $268,441, reflecting a challenging market environment [2][4]. Financial Performance - For Q3 2025, net sales decreased by 26% to $2.26 million from $3.06 million in Q3 2024, while net income fell to $268,441 from $865,484, resulting in a 68% drop in earnings per share to 6 cents from 19 cents [2]. - For the first nine months of 2025, net sales declined 22% to $7.58 million from $9.71 million, and net income decreased to $1.46 million from $2.75 million, with earnings per share down about 47% to 32 cents from 60 cents [2]. Revenue Mix & Key Metrics - The decline in sales was primarily driven by weakness in the cosmetic ingredients business, while sales of pharmaceutical products and medical lubricants increased by 10% and 6%, respectively, over the first nine months of 2025 compared to the same period in 2024 [3]. Market Challenges - The softness in the cosmetic segment is attributed to reduced purchases by Ashland Specialty Ingredients (ASI), the company's largest marketing partner, which has faced tariff and geopolitical challenges in Asia, leading to a shift towards lower-priced local suppliers [4]. - ASI's efforts to manage excess inventory have resulted in decreased orders from United-Guardian, negatively impacting overall sales [4]. Operational Performance - Income from operations fell to $215,072 in Q3 2025 from $949,128 a year earlier, and for the nine months, it decreased to $1.52 million from $3.09 million in 2024 [5]. - Other income sources, including investment income and gains on marketable securities, also declined year-over-year, further dampening overall financial results [5]. Management Insights & Strategic Initiatives - Management remains optimistic about the underlying strength in pharmaceutical and medical businesses, with plans to regain market share through competitive pricing strategies [6]. - Key growth initiatives include focusing on Renacidin, with efforts to secure placement on additional drug formularies to significantly increase sales [7]. - The company has entered a strategic distribution arrangement to expand its sexual wellness and personal care portfolio, aiming to diversify revenue sources and broaden geographic reach [8]. Profitability Factors - Profitability was pressured by an increase in the cost of sales as a percentage of net sales, reflecting product-mix shifts and a challenging pricing environment, particularly in the cosmetic ingredients segment [9]. - Operating expenses rose due to higher professional fees and increased research and development spending, which, while supporting long-term growth, added to near-term earnings pressure [10][11]. Outlook - Although United-Guardian did not provide numerical guidance for the remainder of 2025, management expressed a cautiously optimistic outlook, relying on ASI's efforts to restore competitiveness and distribution expansions to stabilize cosmetic ingredient sales [13]. - The current earnings weakness is viewed as driven more by external demand and inventory dynamics rather than a decline in the company's product portfolio [14]. Shareholder Returns - The company has continued its practice of returning cash to shareholders through dividends, declaring and paying out cash dividends during the first nine months of 2025, including a 35 cents per share dividend earlier in the year [15].

Core Viewpoint - InfuSystem Holdings, Inc. will participate in the 16th Annual Craig-Hallum Alpha Select Conference on November 18, 2025, showcasing its role as a leading national healthcare service provider [1][11]. Company Overview - InfuSystem Holdings, Inc. operates as a national healthcare service provider, facilitating outpatient care for durable medical equipment manufacturers and healthcare providers [3]. - The company utilizes a two-platform model: - **Patient Services**: This segment includes Oncology, Pain Management, and Wound Therapy, focusing on the last-mile solution for clinic-to-home healthcare [3]. - **Device Solutions**: This segment supports Patient Services and includes direct payer rentals, pump and consumable sales, and biomedical services and repair [3]. - InfuSystem is headquartered in Rochester Hills, Michigan, and operates Centers of Excellence in multiple states and Ontario, Canada [3]. Conference Participation - Carrie Lachance, President and CEO, and Barry Steele, CFO, will represent InfuSystem at the conference, which will be held at the Sheraton New York Times Square Hotel [1][2]. - The company will host in-person one-on-one meetings throughout the day for interested investors [2].

Core Viewpoint - The current market is considered expensive, with the Shiller CAPE ratio at 39.6, indicating a potential correction or bear market is likely approaching [1][2] Market Context - Historical data shows that corrections of 10% are common, with the S&P 500 experiencing an average annual correction of at least 10% since 1950, and a 20% correction occurring every three to five years on average [2] Defensive Investment Strategy - Defensive sectors such as healthcare, consumer staples, and utilities are expected to perform well during market corrections and bear markets [3] - Dividend stocks are highlighted as favorable investments during sideways and bear markets due to their income generation [3] Selected Stocks for Mini Portfolio - A mini portfolio of eight stocks, all classified as Dividend Kings (companies that have increased dividends for 50 consecutive years), is recommended for market drawdowns [4] - These stocks are positioned in defensive sectors and offer dividend yields above the S&P 500 index yield of 1.25% [4] Individual Stock Highlights - **Coca-Cola (KO)**: Dividend yield of 2.9%, increased dividends for 63 years, current price around $70.61, market cap $303 billion [5][6] - **Procter & Gamble (PG)**: Dividend yield of 2.86%, increased dividends for 69 years, current price around $147 [7] - **Johnson & Johnson (JNJ)**: Dividend yield of 2.7%, increased dividends for 62 years, current price around $186.57, market cap $450 billion [8][9] - **American States Water (AWR)**: Dividend yield of 2.54%, increased dividends for 71 years, current price around $74.84, market cap $3 billion [10][11] - **Northwest Natural Holding (NWN)**: Highest yield at 4.21%, increased dividends for 70 years, current price around $47 [12] - **Genuine Parts (GPC)**: Dividend yield of 3.3%, increased dividends for 69 years, current price around $127 [13] - **Marzetti Co. (MZTI)**: Dividend yield of 2.21%, increased dividends for 62 years, current price around $172 [13] - **Becton, Dickinson (BDX)**: Dividend yield of 2.35%, increased dividends for 53 years, current price around $178 [14] Total Investment Overview - The total cost to purchase one share of each of these eight stocks is approximately $1,000, creating a defensive income-generating portfolio [15]

Core Insights - Project C.U.R.E. collaborates with Microsoft to enhance global healthcare access and save lives through innovative technology solutions [1][3][6] - Over 4.5 billion people globally lack access to essential health services, with 80% of individuals in low-income countries facing similar challenges [1][2] - Project C.U.R.E. has evolved from a garage startup to a major nonprofit, delivering medical supplies to over 135 countries with the help of 35,000 volunteers [2][7] Technology Integration - The partnership with Microsoft utilizes Dynamics 365, Power Platform, Power BI, and Microsoft Teams to streamline operations and create a data-driven system [3][5] - Automation through Power Platform has reduced manual work from 80% to 15%, improving efficiency in various operational areas [4] - Real-time tracking of financial, inventory, and shipping data enhances accountability and transparency for donors and partners [5] Organizational Impact - The integration of Microsoft technology has led to increased team creativity and energy, positively impacting donor engagement [6] - Project C.U.R.E. aims to leverage technology and compassion to strengthen healthcare systems globally [6]

Table of Contents As filed with the Securities and Exchange Commission on November 4, 2025. Registration No. 333-291112 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Medline Inc. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdiction of incorporation or organization) Delaware 3841 33-1845288 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identi ...

Core Insights - Henry Schein Inc. reported third-quarter adjusted earnings of $1.38, a 13.1% increase year over year, surpassing the consensus estimate of $1.28 [1] - The company's sales totaled $3.34 billion, exceeding the consensus estimate of $3.28 billion, with a net sales increase of 5.2% compared to the third quarter of 2024 [2] Financial Performance - Global Distribution and Value-Added Services sales reached $2.84 billion, up 4.8% [3] - Global Specialty Products sales were $369 million, reflecting a 5.9% increase driven by strong growth in dental implant and endodontics sales [3] - Global Technology sales increased by 9.7% to $173 million, with a 9.0% increase in constant currencies, attributed to the adoption of cloud-based software and new revenue cycle management solutions [4] Share Repurchase and Strategic Moves - During the third quarter, the company repurchased approximately 3.3 million shares at an average price of $68.62 per share, totaling $229 million [5] - Henry Schein has $980 million authorized for future stock repurchases [5] - An amendment to the Strategic Partnership Agreement allows KKR & Co to increase its ownership in Henry Schein stock up to 19.9% through open market purchases [6] Guidance and Future Outlook - The company raised its fiscal 2025 adjusted earnings guidance to a range of $4.88 to $4.96 per share, compared to the previous guidance of $4.80 to $4.94 [7] - Sales guidance was increased from $12.425 billion to $13.180 billion, reflecting a projected sales growth of approximately 3% to 4% over 2024 [7] - Adjusted EBITDA growth for 2025 is expected to increase in the mid-single digits compared to 2024, remaining unchanged [8] Stock Performance - Henry Schein shares rose by 9.48% to $70.77 at the time of publication [8]

Core Insights - InfuSystem reported record net revenues of $36.5 million for Q3 2025, representing a 3% growth from the prior year [1][4][6] - Net income increased by 25% to $2.3 million, with adjusted EBITDA rising 6% to $8.3 million [1][4][15] - The company reaffirmed its full-year 2025 guidance, expecting net revenue growth of 6% to 8% and an adjusted EBITDA margin of 20% or higher [1][18] Financial Performance - Net revenues for Q3 2025 were $36.5 million, up $1.2 million or 3.3% from $35.3 million in Q3 2024 [4][6] - Patient Services segment net revenue was $22.4 million, an increase of 8% year-over-year, while Device Solutions segment net revenue decreased by 3% to $14.1 million [4][7][8] - Gross profit for Q3 2025 was $20.8 million, a 9% increase from the prior year, with a gross margin of 57.1% [4][9] Segment Analysis - Wound care revenue increased by nearly $1.0 million, or 115%, year-over-year, attributed to a new supplier relationship for Pneumatic Compression Devices [3][7] - Oncology revenue saw a record quarter, benefiting from a new contract with a large hospital system [3][7] - Device Solutions segment experienced a decrease in medical equipment sales by $0.8 million, or 33%, but a 5.2% increase in biomedical services revenue [8][11] Cost Management - Selling and marketing expenses decreased by 14.1% to $2.4 million, reflecting a reduction in sales team members and improved cost coverage [12] - General and administrative expenses increased by 12.9% to $14.4 million, driven by IT upgrades and personnel costs related to revenue growth [13] Cash Flow and Liquidity - Year-to-date net operating cash flow was $17.3 million, up 38% compared to the prior year [1][16] - As of September 30, 2025, the company had liquidity of $54.6 million, consisting of $53.6 million in available borrowing capacity and $1.0 million in cash [17] Future Outlook - The company anticipates continued growth in its core business areas and plans to enhance service coverage and pricing through a multi-year extension with a national insurance payer [3][5] - Management is focused on profitable growth and improving operational processes to lower costs [3]